- Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
May 9, 2026
Earnings Call Insights: ALX Oncology (ALXO) Q1 2026
MANAGEMENT VIEW
*
"Most notably, we are very excited to share with you the data set that was presented yesterday in Munich at ESMO Breast 2026 from the analysis of our trial evaluating evorpacept and zanidatamab, which clearly showed again that CD47 expression is a key predictive biomarker for increasing durable clinical response in heavily pretreated HER2-positive patients." (CEO & Director Jason Lettmann)
*
"Here, we observed that all patients who were confirmed HER2-positive and CD47 high achieved a response, including one complete response." (CEO Lettmann) "We also yet again saw the durability that one hopes to see with an IO mechanism with a median duration of response of 20 months and a median PFS of 22 months." (CEO Lettmann)
*
"We added Jeff Knight, who is now our Chief Development and Chief Operating Officer, which really further strengthens our leadership team." (CEO Lettmann)
*
"Our clinical safety database is now more than 800 evorpacept-treated patients." (Chief Medical Officer Barbara Klencke)
*
"We estimate that there are approximately 20,000 addressable patients who are HER2-positive and overexpress CD47, representing a $2 billion to $4 billion market opportunity in the United States, the 5 major European markets and Japan." (CMO Klencke)
*
"As we advance the enrollment and dose escalation in this trial, we are now shifting from providing granular updates to reporting initial safety data in the second half of 2026." (CMO Klencke)
*
No CFO prepared remarks were included in this transcript.
OUTLOOK
*
"Overall, clinical time lines remain on track as we're expected to read out 80 patients mid next year." (CEO Lettmann)
*
"Slide 31 shows our ongoing ASPEN-09 study in the HER2-positive breast cancer setting." (CMO Klencke) "This is going to -- this is a single-arm study that will enroll up to 120 patients and has a primary endpoint of response rate in the subset of patients who overexpress CD47." (CMO Klencke) "We're making very good progress with enrollment, and we're very much on track to achieve our stated milestone of having interim top line data from approximately 80 patients by the middle of 2027." (CMO Klencke)
*
"ALX2004 is also progressing well with enrollment and dose escalation ramping and are on track there for an initial safety readout in the second half of this year." (CEO Lettmann)
FINANCIAL RESULTS
*
The call did not include quarterly revenue, EPS, cash balance, or burn updates; the prepared remarks and Q&A focused on clinical data, trial timelines, and operational milestones.
*
"Q1 was a quarter of continued good execution and additional positive data as well as completion of key hires and a strong financing." (CEO Lettmann)
Q&A
*
Kaiyue Yang, UBS Investment Bank: asked what would be compelling ORR/DOR and whether mPFS would be disclosed for the mid-2027 ASPEN-09 interim readout, and whether CD47 testing would be used clinically; Chief Medical Officer Klencke responded, "a 30% response rate would be a doubling of what we would expect to see without the evorpacept" and said "anything north of 30% would be a very, very good outcome with a duration of 6 months plus," while adding "I would think that PFS might be too immature to report"; Sara Hurvitz said, "if CD47 is validated as being a predictive marker for benefit from evorpacept, then I do think we will be probably seeing it developed as a companion diagnostic." (Chief Medical Officer Klencke; Sara Hurvitz)
*
Derek Archila, Wells Fargo: asked how ASPEN-09 compares to the presented population, the CD47 cutoff assumptions behind the 20,000 estimate, and how the zani combination affects development; CEO Lettmann said, "I think the beauty of this design that we're pursuing now is it's effectively the same," and added the company will take Evo forward "in combination with an Fc active antibody"; CMO Klencke said ASPEN-09 is intended to determine "what's the optimal cut point" and cited prior gastric work with cut points ranging "from 45% to 57%." (CEO Lettmann; CMO Klencke)
*
Ashleigh Acker, Piper Sandler: asked for an update on companion diagnostic development and whether biomarker validation changes ASPEN-09 statistical powering; CMO Klencke said, "The Ventana Laboratory is our partner. We are working right now on developing a companion diagnostic," and CEO Lettmann said, "we're not going to power the study at 100% ORR" while describing the targeted strategy as enabling "a much more targeted Phase III." (CMO Klencke; CEO Lettmann)
*
Daniel Bronder, Cantor Fitzgerald: asked about HER2 concordance details and whether the company is ruling out accelerated approval; CMO Klencke said, "if we do" replicate extraordinary response "we would talk to the health authorities, U.S. FDA about an accelerated approval strategy," but added, "that is not our base case" and "a Phase III trial will be required"; Sara Hurvitz described factors behind discordance and said, "the testing changed from local to central and also from archival tissue to fresh tissue." (CMO Klencke; Sara Hurvitz)
*
Jiale Song, Jefferies: asked whether early ASPEN-09 screening supports roughly half being CD47-high and whether tissue/turnaround time gates enrollment; CEO Lettmann said the company will "disclose that when we get to the data readout on 80 patients," and CMO Klencke emphasized "The ASPEN-09 study enrolls patients irrespective of CD47." (CEO Lettmann; CMO Klencke)
*
Oliver McCammon, LifeSci Capital: asked about differences between the 20% total membrane staining definition vs. prior cutoffs; CMO Klencke explained total membrane staining as cumulative scoring and said, "we will look again once we have data from ASPEN-09 and optimize that." (CMO Klencke)
SENTIMENT ANALYSIS
*
Analysts were slightly positive and primarily focused on biomarker strategy execution and regulatory pathway, with questions framing enthusiasm but pressing on practicalities such as "compelling results" and whether accelerated approval is possible. (Kaiyue Yang, UBS Investment Bank; Daniel Bronder, Cantor Fitzgerald)
*
Management sentiment was positive in prepared remarks and remained steady in Q&A, repeatedly emphasizing confidence in the data package and timeline execution, including "remain well positioned to report on significant data readouts" and "we are very much on track" for mid-2027 interim data. (CEO & Director Jason Lettmann; Chief Medical Officer Barbara Klencke)
*
Versus last quarter, the current call’s tone leaned more data-driven around the ESMO Breast biomarker analysis, while the prior call blended clinical updates with financing runway and GAAP metrics. (CEO Lettmann; Chief Financial Officer Harish Shantharam)
QUARTER-OVER-QUARTER COMPARISON
*
The current call centered on the ESMO Breast 2026 biomarker dataset; CEO Lettmann said it "clearly showed again that CD47 expression is a key predictive biomarker," whereas the prior call previewed that "Full biomarker analysis from this trial is expected to be presented at a medical conference in Q2 of this year." (CEO & Director Jason Lettmann)
*
Leadership updates shifted: the current call introduced "Jeff Knight" as "Chief Development and Chief Operating Officer" (CEO Lettmann), while the prior call announced, "Barb will continue leading our clinical efforts as our permanent Chief Medical Officer." (CEO & Director Jason Lettmann)
*
Financial disclosure intensity declined: last quarter CFO Shantharam reported "net proceeds" of "$140.4 million" and runway "through the first half of 2028," plus GAAP net loss and per-share figures; this quarter provided no comparable financial line items. (Chief Financial Officer Harish Shantharam)
RISKS AND CONCERNS
*
"Those patients who did not have centrally confirmed HER2-positive disease had a lower objective response rate of 14%." (Sara Hurvitz)
*
"Although these numbers are very small, we're talking about 9 patients total." (Sara Hurvitz)
*
"I think regulatory approvals for single-arm trials when you have a combination of two agents, very difficult to get an accelerated approval." (Chief Medical Officer Barbara Klencke) "It's also true that it's very difficult to get an accelerated approval with retrospective application of a companion diagnostic." (CMO Klencke)
FINAL TAKEAWAY
Management emphasized the ESMO Breast 2026 biomarker analysis as validation for a CD47-guided strategy in HER2-positive metastatic breast cancer, highlighting that centrally confirmed HER2-positive, CD47-high patients in the zani-Evo study all responded with durable outcomes cited as a 20-month median duration of response and 22-month median PFS, while positioning ASPEN-09 to deliver interim topline data from approximately 80 patients by mid-2027 and advancing ALX2004 toward an initial safety readout in the second half of 2026.
Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/alxo/earnings/transcripts]
MORE ON ALX ONCOLOGY
* ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4901743-alx-oncology-holdings-inc-alxo-q1-2026-earnings-call-transcript]
* ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4901741-alx-oncology-holdings-inc-2026-q1-results-earnings-call-presentation]
* ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones [https://seekingalpha.com/article/4876841-alx-oncology-evorpacept-for-aspenminus-09-presses-on-with-2-key-milestones]
* ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing [https://seekingalpha.com/news/4558937-alx-oncology-outlines-pivotal-trial-readiness-by-end-of-2026-with-expanded-aspenminus-09]
* Seeking Alpha’s Quant Rating on ALX Oncology [https://seekingalpha.com/symbol/ALXO/ratings/quant-ratings]
- ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
May 9, 2026 · seekingalpha.com
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
- ALX Oncology Q1 Earnings Call Highlights
May 8, 2026 · marketbeat.com
ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.
- ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026 · globenewswire.com
- Data from Phase 1b/2 trial of evorpaceptzanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer - - Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 - - Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 - - ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and Operating Officer - - Company to host webcast including presentation of ESMO Breast data by breast cancer expert Sara Hurvitz, M.
- ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026 · globenewswire.com
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -
- ALX ONCOLOGY REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
May 8, 2026
- DATA FROM PHASE 1B/2 TRIAL OF EVORPACEPT + ZANIDATAMAB PRESENTED AT ESMO BREAST CANCER 2026 SHOWED ALL PATIENTS WITH CONFIRMED HER2-POSITIVE DISEASE AND HIGH CD47 EXPRESSION EXPERIENCED DURABLE RESPONSES TO THIS COMBINATION -
- ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
May 7, 2026
ALX Oncology
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -
- Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression could potentially serve as an important predictive biomarker of evorpacept activity -
- ALX Oncology will host a webcast on May 8 to report first quarter 2026 financial results; breast cancer expert will discuss the evorpacept + zanidatamab trial results in detail -
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that data from exploratory analyses in the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab (ZIIHERA®) in patients with heavily pre-treated HER2-positive metastatic breast cancer (mBC) were presented for the first time today in a poster session at the ESMO Breast Cancer 2026 congress. The findings show that patients with centrally confirmed HER2-positive (ccHER2-positive) mBC and high CD47 expression experienced a promising, durable response.
Specifically, patients in the trial with ccHER2-positive disease and high CD47 expression (defined as total membrane staining of >20%) had a confirmed objective response rate (cORR) of 100% (n=5/5), while the cORR was 25% (n=1/4) among those with lower CD47 expression (<20%). Those patients whose tumors expressed higher levels of CD47 also had longer median progression-free survival (mPFS): 22.1 months as compared to 3.4 months in the low-CD47 expression group. The median duration of response (mDOR) among patients whose tumors expressed high levels of CD47 was also notable at 20.2 months.
“There is a large and growing population of patients with advanced breast cancer who need novel treatment options once their disease has progressed following treatment with currently available therapies, including trastuzumab deruxtecan,” said Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, who presented the findings today. “Our data suggest that adding evorpacept to HER2-targeted agents may provide one such option, and we may be able to optimize patient selection for these regimens by using a biomarker-driven approach that incorporates CD47.”
Story Continues
The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zanidatamab included patients with heavily pre-treated HER2-positive mBC (median of five prior HER2-targeted therapies), all of whom had received prior ENHERTU therapy. The primary trial results, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), demonstrated that the investigational combination generated promising anti-tumor activity and a manageable safety profile.
The exploratory analyses comprised 24 patients, including 10 with ccHER2-positive disease. Seventeen of 24 samples were evaluable for CD47 expression, including samples from nine of the 10 ccHER2-positive patients. Patients received zanidatamab plus evorpacept at dosages of 20 mg/kg (n=3) or 30 mg/kg (n=21). As of the August 1, 2024 data cut-off, key findings from the analyses include:
The cORR among all 24 patients was 33% and the mPFS was 3.6 months. Patients with ccHER2-positive disease (n=10) had higher response rates, with a cORR of 60% and mPFS of 8.3 months. All of the patients (n=5/5) with ccHER2-positive disease and high CD47 expression (defined as total membrane staining of >20%) responded (including one complete response and four partial responses), with an mDOR of 20.2 months and mPFS of 22.1 months. In comparison, among the patients with ccHER2-positive disease and low CD47 expression (defined as total membrane staining of <20%), cORR was 25% (n=1/4) and mPFS was 3.4 months.
“The findings from these exploratory analyses provide additional evidence that adding evorpacept to HER2-targeted therapies may generate durable responses in heavily pretreated HER2-positive breast cancers, including in patients in the post-ENHERTU setting,” said Barbara Klencke, M.D., Chief Medical Officer at ALX Oncology. “They also further support the use of a biomarker-driven approach to predict treatment response, as we previously observed in the HER2-positive gastric cancer setting. We designed the ongoing ASPEN-09-Breast Phase 2 trial of evorpacept plus trastuzumab and chemotherapy to provide additional insight into this approach and, we hope, move closer to delivering a new therapeutic option for this group of patients.”
Q1 2026 Results Conference Call and Webcast Details
ALX Oncology management will host a webcast tomorrow (Friday, May 8), to provide an overview of Q1 2026 financial results. Sara Hurvitz, M.D., will join the call to discuss and provide perspective on the Phase 1b/2 trial data shared at the ESMO Breast Cancer congress.
Date & Time: Friday, May 8, 2026, 8:30 a.m. ET
Guest Speaker: Sara Hurvitz, M.D., Professor, Senior Vice President and Director, Clinical Research Division and Smith Family Endowed Chair in Women’s Health at Fred Hutchinson Cancer Center; Professor and Head, Division of Hematology and Oncology, Department of Medicine, University of Washington
Webcast Access: https://viavid.webcasts.com/starthere.jsp?ei=1758590&tp_key=2800839c82
Participant Listening Options by Phone: To access the conference call, please dial 1-877-407-0752 or +1-201-389-0912 and ask to be joined into the ALX Oncology First Quarter 2026 Financial Results Conference Call.
Another option for instant telephone access to the event is to use the Call Me™ link below:
https://callme.viavid.com/viavid/?callme=true&passcode=13755276&h=true&info=company&r=true&B=6
A live audio webcast of the call, along with the ALX Oncology corporate presentation, will be available under "Events & Presentations" in the Investor section of the Company's website, www.alxoncology.com. An archived webcast will be available on the Company's website after the event.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
View Comments
- ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
May 7, 2026 · globenewswire.com
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -
- ALX ONCOLOGY'S EVORPACEPT IN COMBINATION WITH ZANIDATAMAB GENERATES PROMISING, DURABLE RESPONSE IN PATIENTS WITH ADVANCED HER2-POSITIVE BREAST CANCER AND HIGH CD47 EXPRESSION
May 7, 2026
- DATA FROM PHASE 1B/2 TRIAL PRESENTED AT ESMO BREAST CANCER 2026 FURTHER VALIDATE A BIOMARKER-DRIVEN DEVELOPMENT STRATEGY FOR EVORPACEPT -
- ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
Apr 30, 2026
ALX Oncology
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 -
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on May 7.
The ESMO Breast Cancer poster presentation will highlight data from exploratory analyses conducted to identify biomarkers predictive of response to the evorpacept + zanidatamab regimen.
The Company also announced it will report first quarter 2026 financial results on Friday, May 8, 2026, before market open. Management will host a conference call at 8:30 a.m. ET to review Q1 financial results, and guest speaker Sara Hurvitz, M.D., Professor, Senior Vice President and Director, Clinical Research Division and Smith Family Endowed Chair in Women’s Health at Fred Hutchinson Cancer Center, will discuss and share her perspective on the ESMO Breast Cancer clinical data.
The ESMO Breast Cancer presentation will feature data from an exploratory biomarker analysis of patients with HER2-positive mBC in the evorpacept + zanidatamab Phase 1b/2 trial. Topline data from this analysis, which ALX Oncology announced in January 2026, indicate that the responses were largely restricted to patients with higher CD47 expression. These results reinforce data from the ASPEN-06 clinical trial, which previously demonstrated that CD47 expression could potentially serve as an important predictive biomarker for response and durable benefit in patients with advanced gastric cancer who retained HER2 expression.
ESMO Breast Cancer 2026 Presentation Details
Title: Exploratory biomarker analysis from a phase 1b/2 trial of zanidatamab + evorpacept in patients with HER2-positive metastatic breast cancer
Date & Time: Thursday, May 7, 2026, 7:15 am ET / 13:15 CEST
Abstract Number: 561
Poster Number: 72P
Presenter: Funda Meric-Bernstam, MD, Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center
Q1 2026 Results Conference Call and Webcast Details
Date & Time: Friday, May 8, 2026, 8:30 am ET
Guest Speaker: Sara Hurvitz, MD, Professor, Senior Vice President and Director, Clinical Research Division and Smith Family Endowed Chair in Women’s Health at Fred Hutchinson Cancer Center; Professor and Head, Division of Hematology and Oncology, Department of Medicine, University of Washington
Story Continues
Webcast Access: https://viavid.webcasts.com/starthere.jsp?ei=1758590&tp_key=2800839c82
Participant Listening Options by Phone: To access the conference call, please dial 1-877-407-0752 or +1-201-389-0912 and ask to be joined into the ALX Oncology First Quarter 2026 Financial Results Conference Call.
Another option for instant telephone access to the event is to use the Call Me™ link below:
https://callme.viavid.com/viavid/?callme=true&passcode=13755276&h=true&info=company&r=true&B=6
A live audio webcast of the call, along with the ALX Oncology corporate presentation, will be available under "Events & Presentations" in the Investor section of the Company's website, www.alxoncology.com. An archived webcast will be available on the Company's website after the event.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1 dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
View Comments
